SocialPicks Sentiment:
** v.s.
other stocks
|
This Quarter's Sentiment:
|
|
|
SocialPicks Community
From the Blogosphere
King Beats, but Earnings Down – Analyst Blog
|
|
|
King Pharmaceuticals, Inc. (KG) reported third quarter earnings of 29 cents per share, beating the Zacks Consensus Estimate by 2 cents. Despite revenues increasing 19.3% from the year-ago period, earnings declined 25.6% from the year-ago quarter mainly due to higher operating expenses.
Total revenues came in at $463.3 million. The primary growth drivers were the Animal Health business, which came as a part of the Alpharma acquisition and an increase in sales of auto-injectors in the Meridian business.
King’s branded pharmaceuticals segment posted revenues of $283 million, down 6.3% from the p< />< /><><><><>< />< /><>< />< />< />< />< />< />< />< />< />< /><><>< /><>< /><>< /><>< /><>< /><>< /><>< /><><>< /><>< /><>< />< />...
|
Top 40 Rated Emerging Bio-Pharma Stocks
|
|
|
The accompanying table [click to enlarge] highlights the Top 40 Rated stocks (sorted alphabetically) in the ETF Innovators [ETFI] Emerging Bio-Pharma Index of biotech and pharmaceutical companies with market caps of $200M-$1.5B. The rating system factors in each company's number of innovative clinical pipeline + marketed products, market cap weighting, and historical stock price return.
The Emerging Bio-Pharma Index has outpaced benchmark ETFs such as iShares Nasdaq Biotech (IBB), PowerShares Dynamic Pharma (PJP), and the Healthcare Sector SPDR (XLV) over the past year. Since I last updated ...
|
Top 40 Rated Emerging Bio-Pharma Stocks
|
|
|
The accompanying table [click to enlarge] highlights the Top 40 Rated stocks (sorted alphabetically) in the ETF Innovators [ETFI] Emerging Bio-Pharma Index of biotech and pharmaceutical companies with market caps of $200M-$1.5B. The rating system factors in each company's number of innovative clinical pipeline + marketed products, market cap weighting, and historical stock price return.
The Emerging Bio-Pharma Index has outpaced benchmark ETFs such as iShares Nasdaq Biotech (IBB), PowerShares Dynamic Pharma (PJP), and the Healthcare Sector SPDR (XLV) over the past year. Since I last updated ...
|
Breast implant maker stock expands 90%
Filed under: Deals, Johnson and Johnson (JNJ)  Johnson & Johnson (NYSE: JNJ) offered to acquire breast implant maker Mentor Corp (NYSE: MNT). At $31 per share, J&J's tender offer for Mentor is a 92% premium to its closing price last Friday.
<>J&J plans to run the $373 million Mentor as a standalone business under its Ethicon division, reasoning that the skills of its 1,300 employees will strengthen J&J's presence in aesthetic and reconstructive medicine. Mentor is not just about breast implants -- mostly for cancer patient reconstruction. It is also awaiting FDA approval for face fillers, which...
|
Morning Movers 11/24: Citi (C) Up on Treasury/Fed Rescue Package, Financials Follow (BAC, MS, GS, WFC, JPM)
<>StreetInsider.com Morning Movers
LandAmerica Financial (NYSE: LFG) 83% LOWER; LandAmerica, Fidelity National deal terminated
Citigroup, Inc. (NYSE: C) 57% HIGHER; Treasury, Fed Rescues Citi (C) With $40B Package
Omrix Biopharmaceuticals, Inc. (NASDAQ: OMRI) 16% HIGHER; Johnson & Johnson (NYSE: JNJ) To Acquire Omrix Biopharmaceuticals (OMRI) For $25/Share
TASER International Inc. (NASDAQ: TASR) 13% HIGHER; Los Angeles Police Department Upgrades TASER Program
CBRL Group (Nasdaq: CBRL) 12% HIGHER; reports Q1 earnings of $0.57 per share, above the consensus of $0.52. Revenues came in at $573.9 m...
|
|
ROCK-STAR INVESTORS
|
|
POPULAR STOCKS
|
|
TODAY'S HEADLINES
|
|
TODAY'S TOP PICKS
|
|
|
| StreetInsider.com on OMRI |
Visit streetinsider.com
Be the first to start a discussion and earn 2 points.
More Resources
|
About Omrix Biopharmaceuticals Inc.
- Answers.com
